Related Experiment Video
Updated: Jun 11, 2025
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
The prognostic value of hydroxybutyrate dehydrogenase in diffuse large B cell lymphoma
Junyu Zhang1, Bocheng Chen1, Cangjian Zhang1
1Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, P.R. China.
Insights
Hydroxybutyrate dehydrogenase (HBDH) is a key predictor for diffuse large B cell lymphoma (DLBCL) patients. Elevated HBDH levels indicate poor progression-free survival (PFS) and may help evaluate patient outcomes.
Area of Science:
- Biochemistry
- Oncology
- Biomarker Discovery
Background:
- Diffuse large B cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Identifying reliable biomarkers for progression-free survival (PFS) is crucial for managing DLBCL patients.
Purpose of the Study:
- To investigate biochemical parameters as potential biomarkers for DLBCL progression-free survival (PFS).
- To validate the predictive value of hydroxybutyrate dehydrogenase (HBDH) in DLBCL patient cohorts.
Main Methods:
- Analysis of biochemical parameters in 100 DLBCL patients for initial biomarker identification.
- Validation of findings in an independent cohort of 404 DLBCL patients.
- Metabolic and genetic pathway enrichment analyses to understand HBDH's role.
Main Results:
- Elevated hydroxybutyrate dehydrogenase (HBDH) levels were strongly associated with poor progression-free survival (PFS) in DLBCL patients.
- HBDH expression was a more robust predictor of clinical prognosis than lactate dehydrogenase (LDH) expression.
- Heightened HBDH expression correlated with distinct pathways in energy metabolism and lymphoma progression.
Conclusions:
- Elevated HBDH levels are correlated with adverse survival outcomes in DLBCL.
- HBDH may serve as an independent prognostic parameter for evaluating DLBCL patient outcomes.
- HBDH's association with specific metabolic pathways highlights its role in lymphoma progression.
Abstract:
In our investigation, we examined biochemical parameters and identified hydroxybutyrate dehydrogenase (HBDH) as a significant predictor for diffuse large B cell lymphoma (DLBCL) patients. A group of 100 patients was used to explore potential biomarkers related to progression-free survival (PFS). Subsequently, an independent cohort of 404 patients from a separate hospital was recruited to validate our findings. Our results revealed a strong association between elevated HBDH levels and poor PFS. Furthermore, although overexpression of LDHB, but not LDHA, was notably linked to poorer outcomes, HBDH expression emerged as a more robust predictor of clinical prognosis compared to LDH expression. Our investigations, which included metabolic and genetic pathway enrichment analyses, indicated that patients exhibiting heightened HBDH expression were characterized by distinct pathways related to energy metabolism and lymphoma progression. In conclusion, elevated HBDH levels were correlated with adverse survival and might serve as an independent parameter for evaluating patient outcomes.
